We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-3.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.78B
AUM Growth
+$176M
Cap. Flow
-$78M
Cap. Flow %
-2.8%
Top 10 Hldgs %
39.13%
Holding
109
New
17
Increased
24
Reduced
19
Closed
12

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$94.3M
2
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$60.3M
3
AERI
Aerie Pharmaceuticals
AERI
+$54.9M
4
XENT
Intersect ENT, Inc
XENT
+$29.7M
5
CHRS icon
Coherus Oncology
CHRS
+$29.1M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$90.8M
2
CNC icon
Centene
CNC
+$19.7M
3
AXGN icon
Axogen
AXGN
+$18.7M
4
GKOS icon
Glaukos
GKOS
+$17.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$17M

Sector Composition

Rank Sector Weight
1 Healthcare 67.69%
2 Financials 0.96%
3 Consumer Discretionary 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOR
51
DELISTED
MorphoSys AG American Depositary Shares
MOR
$14.5M 0.52%
600,000
– –
RYTM icon
52
Rhythm Pharmaceuticals
RYTM
$7.25B
$13.7M 0.49%
623,933
+332,928
+114% +$8.41M
DCPH
53
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$13.7M 0.49%
607,633
– –
LKFT
54
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.94B
$13M 0.47%
101,010
-75,948
-43% -$9.01M
GBT
55
DELISTED
Global Blood Therapeutics, Inc.
GBT
$12.4M 0.44%
+235,000
New +$13.5M
ATNX
56
DELISTED
Athenex, Inc. Common Stock
ATNX
$12.3M 0.44%
31,093
– –
SYRS
57
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$11.8M 0.42%
126,895
– –
TPTX
58
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$11.7M 0.42%
+287,545
New +$10.3M
PHAS
59
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$11.2M 0.4%
+851,005
New +$10.4M
SYBX
60
DELISTED
Synlogic
SYBX
$10.1M 0.36%
73,843
– –
TNDM icon
61
Tandem Diabetes Care
TNDM
$1.19B
$9.84M 0.35%
152,500
+117,000
+330% +$7.55M
ARDX icon
62
Ardelyx
ARDX
$1.29B
$9.31M 0.33%
3,461,298
+177,000
+5% +$533K
INSP icon
63
Inspire Medical Systems
INSP
$1.49B
$9.16M 0.33%
151,106
+12,106
+9% +$653K
CHWY icon
64
Chewy
CHWY
$8.56B
$9.15M 0.33%
+261,337
New +$8.83M
ACRS icon
65
Aclaris Therapeutics
ACRS
$782M
$8.72M 0.31%
3,983,025
-1,910,391
-32% -$10.4M
XFOR icon
66
X4 Pharmaceuticals
XFOR
$355M
$8.47M 0.3%
+18,833
New +$9.57M
AVDL
67
DELISTED
Avadel Pharmaceuticals
AVDL
$7.87M 0.28%
2,722,241
– –
BBIO icon
68
BridgeBio Pharma
BBIO
$16B
$7.82M 0.28%
+290,000
New +$7.91M
SRNE
69
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$5.58M 0.2%
+2,091,461
New +$7.53M
ALIM
70
DELISTED
Alimera Sciences
ALIM
$5.39M 0.19%
403,529
– –
IDYA icon
71
IDEAYA Biosciences
IDYA
$3.47B
$4.23M 0.15%
+425,000
New +$4.62M
BDSI
72
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.79M 0.14%
+816,096
New +$3.8M
HARP
73
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$3.71M 0.13%
28,500
– –
MDCO
74
PUT
DELISTED
Medicines Co
MDCO
$3.65M 0.13%
+100,000
New +$3.26M
ITMR
75
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$3.46M 0.12%
314,136
– –
1 2
3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2019 Portfolio in Review

As of Q2 2019, Deerfield Management held 109 positions worth $2.78B, up 6.8% from $2.61B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Deerfield Management's Q2 2019 filing shows 17 new, 24 increased, 19 reduced and 12 closed positions. Its largest new stake was MALLINCKRODT PUBLIC LIMITED COMPANY: 4,178,219 shares worth $38.4M. The largest sale was Portola Pharmaceuticals, Inc., an estimated $90.8M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 69% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Deerfield Management's largest Q2 2019 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 4,178,219 shares worth $38.4M.
  • Deerfield Management added most to Viatris in Q2 2019, an estimated $94.3M increase.
  • Deerfield Management's biggest Q2 2019 reduction was Centene, cutting an estimated $19.7M.
  • Deerfield Management fully exited Portola Pharmaceuticals, Inc. in Q2 2019, selling an estimated $90.8M.
  • Deerfield Management's ten largest holdings make up 39% of its $2.78B portfolio in Q2 2019.
  • Deerfield Management opened 17 new positions and closed 12 in Q2 2019.
  • Deerfield Management's portfolio value rose 6.8% quarter-over-quarter to $2.78B.

Based on Deerfield Management's 13F filing for Q2 2019, filed 14 Aug 2019.